ATAI News and Press, ATAI Life Sciences N.V. From 01/08/23

Summary What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management. He shares what investors should focus on in the sector and the pros and cons of owning his top 5 psychedelic stocks. ...

Shares of Atai Life Sciences (Nasdaq: ATAI) plunged by more than 40% after phase 2a clinical trial results looking at ketamine therapy to treat depression failed to meet its primary endpoint. Atai said that while findings showed “signals of efficacy across all timepoints out to two...

Atai Life Sciences ( NASDAQ: ATAI ) said its majority-owned unit Perception Neuroscience's therapy PCN-101 (R-ketamine)  did not meet the main goal of a phase 2a trial for treatment-resistant depression. The study evaluated efficacy of a single IV administration of PCN-1...

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across a...

Every few years, new or previously forgotten discoveries shake up the very foundation of how industries operate. The development of the internet, for instance, altered society in a multitude of ways, enabling previously unknown ways of connecting and thinking and completely revolutionizing how ...

-   This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 -   KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models -   An as...

The landscape for success with psychedelics companies is still shaping up, with more companies getting into the space or developing partnerships to help them grow faster and do more with their resources. The year 2022 has been a story of shifting personnel, big buyouts and collaborations, new...

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS). The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-ye...

NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massa...

Summary Welcome to the first ever Psychedelic Sunday episode! There is a lot of overlap between the cannabinoid and psychedelic experiences and today we launch our coverage of the psychedelics industry. Challenges and opportunities within psychedelics. Highlighting 4 stocks: Com...